Evommune Licenses Hinova Autoimmune Drug
Evommune acquired a license to Hinova’s autoimmune drug.
Related stories
Digital Realty and Goodman Seek Nearly 10% Stake in NextDC
NextDC said Digital Realty Trust and Goodman Group teamed up in an attempt to buy nearly 10% of its stock.
M impact | MNA | Nov 04, 2026, 11:48 PM UTC
AstraZeneca reportedly makes an offer for Rhythm Pharmaceuticals
According to some sources, AstraZeneca has made an offer for the obesity-drug maker.
M impact | MNA | Nov 04, 2026, 10:56 PM UTC
Evommune Licenses Hinova Autoimmune Drug in Deal Worth Up to $1.1 Billion
Evommune said it licensed rights to an experimental autoimmune disease treatment from China's Hinova Pharmaceuticals, with up to about $1.1 billion in milestone payments.
M impact | MNA | Nov 04, 2026, 10:24 PM UTC
AstraZeneca Offers for Rhythm, Sources Say
AstraZeneca made an offer for Rhythm, according to sources.
M impact | MNA | Nov 04, 2026, 10:20 PM UTC
Dover Completes Acquisition of Leistung Engineering
Dover completed its acquisition of Leistung Engineering on November 4, 2026.
M impact | MNA | Nov 04, 2026, 10:10 PM UTC
Agility Robotics, Churchill Capital XI Complete Business Combination
Agility Robotics completed its business combination with Churchill Capital Corp XI.
M impact | MNA | Nov 04, 2026, 09:32 PM UTC